Latest Advances in Lung Cancer Research

Fred Hutchinson Cancer Center received a $30 million NCI grant to enhance cancer research and support vital services for the next five years.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

Study reveals 1 in 12 advanced lung cancer patients died from COVID-19 during the Omicron wave, highlighting the variant’s significant risk despite lower severity.

At 22, Leah Hubbard faces advanced lung cancer potentially linked to teenage pregnancy, challenging assumptions about the disease and raising awareness.

At the 2023 World Conference, lung cancer advocacy triumphed with a 25% funding boost for the Lung Cancer Research Program, thanks to strategic lobbying and a unified advocacy platform.

Study reveals multiple pregnancies and extended breastfeeding reduce women’s lung cancer risk, suggesting reproductive factors influence cancer screening and prevention.

Experts recommend enhanced lung cancer screening, accessible treatments, and increased research funding to prevent deaths and support affected individuals.

VA study reveals unique cancer patterns in Native American and Alaska Native veterans, informing tailored care and prevention efforts.

A study reveals that Black lung cancer patients are diagnosed younger and with more advanced stages than white patients, highlighting racial disparities in healthcare.

New US guidelines lower lung cancer screening age to 50 and reduce smoking history requirement to 20 pack-years, expanding preventative scans to save more lives.

The FDA granted orphan drug status to Quratusugene ozeplasmid, a promising gene-based therapy for small cell lung cancer, to expedite its development.